Estimating effects of whole grain consumption on type 2 diabetes, colorectal cancer and cardiovascular disease: a burden of proof study
Liu H, Zhu J, Gao R, Ding L, Yang Y, Zhao W, Cui X, Lu W, Wang J, Li Y
Nutrition journal · 4 citas
Etiquetas de revisión
Sin ajuste declarado por estilo de vidaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Estudio de cohortes (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Eventos clínicos como enfermedad o muerte
- Consumo medido con
- No se indica
Quién lo pagó
- Financiación
- Financiación independiente
- Universidad u hospital
- the Key Discipline of Zhejiang Province in Public Health and Preventative Medicine (First Class, Category A), Hangzhou Medical College
Según 1 financiador declarado y la declaración de financiación del texto completo.
Publicación
- Publicado
- 2024-05-14 · Nutr J · vol. 23 · número 1 · pág. 49
- Editorial
- BioMed Central
- Citado
- 10 citas · más que el 86% de estudios similares · 2.1× el promedio de su campo
- Referencias
- 58 trabajos
- Acceso
- Acceso abierto (revista) · CC-BY
- Áreas de investigación
- Food composition and properties · Nutritional Studies and Diet · Celiac Disease Research and Management
- Palabras clave
- Medicine, Stroke (engine), Colorectal cancer, Relative risk, Type 2 diabetes, Refined grains, Cohort study, Disease, Internal medicine, Prospective cohort study, Diabetes mellitus, Whole grains, Confidence interval, Cancer, Endocrinology, Food science
- MeSH
- humans, colorectal neoplasms, cardiovascular diseases, diabetes mellitus, type 2, diet, risk factors, prospective studies, whole grains
10 autores
- Houpu Liu🇨🇳Hangzhou Medical College
- Jiahao Zhu🇨🇳Hangzhou Medical College
- Rui Gao🇨🇳Hangzhou Medical College
- Lilu Ding🇨🇳Hangzhou Medical College
- Ye Yang🇨🇳Hangzhou Medical College
- Wenxia Zhao🇨🇳Hangzhou Medical College
- Xiaonan Cui🇨🇳Tianjin Medical University Cancer Institute and Hospital
- Wenli Lu🇨🇳Tianjin Medical University
- Jing Wang🇨🇳 · autor de correspondenciaHangzhou Medical College
- Yingjun Li🇨🇳 · autor de correspondenciaHangzhou Medical College
Resumen
El texto original del estudio, en el idioma en que se publicó.
Background
Previous studies on whole grain consumption had inconsistent findings and lacked quantitative assessments of evidence quality. Therefore, we aimed to summarize updated findings using the Burden of Proof analysis (BPRF) to investigate the relationship of whole grain consumption on type 2 diabetes (T2D), colorectal cancer (CRC), stroke, and ischemic heart disease (IHD).
Methods
We conducted a literature search in the Medline and Web of Science up to June 12, 2023, to identify related cohort studies and systematic reviews. The mean RR (relative risk) curve and uncertainty intervals (UIs), BPRF function, risk-outcome score (ROS), and the theoretical minimum risk exposure level (TMREL) were estimated to evaluate the level of four risk-outcome pairs.
Results
In total, 27 prospective cohorts were included in our analysis. Consuming whole grain at the range of TMREL (118.5-148.1 g per day) was associated with lower risks: T2D (declined by 37.3%, 95% UI: 5.8 to 59.5), CRC (declined by 17.3%, 6.5 to 27.7), stroke (declined by 21.8%, 7.3 to 35.1), and IHD (declined by 36.9%, 7.1 to 58.0). For all outcomes except stroke, we observed a non-linear, monotonic decrease as whole grain consumption increased; For stroke, it followed a J-shaped curve (the greatest decline in the risk of stroke at consuming 100 g whole grain for a day). The relationships between whole grain consumption and four diseases are all two-star pairs (ROS: 0.087, 0.068, 0.062, 0.095 for T2D, CRC, stroke, and IHD, respectively).
Conclusion
Consuming 100 g of whole grains per day offers broad protective benefits. However, exceeding this threshold may diminish the protective effects against stroke. Our findings endorse replacing refined grains with whole grains as the main source of daily carbohydrates. REGISTRY AND REGISTRY NUMBER FOR SYSTEMATIC REVIEWS OR META-ANALYSES: We have registered our research in PROSPERO, and the identifier of our meta-analyses is CRD42023447345.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial (CC BY).
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.